ABSTRACT
ObjectiveTo investigate the antitumor effect of cyclooxygenase-2 (COX-2) antisense RNA combined with celecoxib on hepatoma CBRH7919 cells. MethodsThe effect of celecoxib on in vitro proliferative activity, cell cycle, and apoptosis of hepatoma cell lines CBRH7919, CBRH7919-E, and CBRH7919-A (transfected with COX-2 antisense gene segment) were observed. MTT assay, cell cycle analysis, and RT-PCR were used to evaluate the change in in vitro proliferation of hepatoma cell lines. A multivariate analysis of variance was used for comparison of continuous data between groups, and the SNK-q test was used for further comparison between two groups. ResultsAfter the treatment with celecoxib, CBRH7919-A cells had a significant reduction in growth rate compared with CBRH7919 and CBRH7919-E cells (F=38.303, P＜0.01), in a time- and dose-dependent manner (F=162.638 and 22.666, both P＜0.01). Celecoxib significantly increased the proportion of cells in G0/G1 phase and had a marked inhibitory effect on cells in S phase in a dose-dependent manner (F=32.515, P＜0.01), while there was no significant change in the proportion of cells in G2/M phase. Compared with CBRH7919 and CBRH7919-E cells, CBRH7919-A cells were more sensitive to celecoxib (F=1219.506, P＜0.01). After the treatment with celecoxib at different concentrations (40 and 80 μmol/L), all three groups had a significant increase in cell apoptosis (all P＜001), and there was no significant difference in apoptosis between the three groups (P＞0.05). ConclusionCOX-2 antisense RNA combined with celecoxib can inhibit the in vitro growth and proliferation and cell cycle of hepatoma CBRH7919 cells, promote apoptosis, and thus exert a potential therapeutic effect on hepatoma cells.
ABSTRACT
Objective To investigate the different doses of dexmedetomidine on reducing the effects of restlessness after anesthesia.Methods Forty-eight patients who occurred restlessness after general anesthesia were collected and randomly divided into A,B,C group (16 cases in each group).Dexmedetomidine were given at dose of 0.3 μg/kg,0.5 μg/kg,1.0 μg/kg for treatment as A,B,C group.Blood pressure,heart rate,Riker sedation-restlessness (SAS) score and other changes of patients were recorded at different time points after treatment.Results SAS scores were significantly lower in B,C groups than that in A group (P ＜ 0.05) at immediately after administration and 5 min and 10 min after administration.Systolic pressure and heart rate were significantly lower in C group than in B,A group (P ＜ 0.05) at immediately after administration and 5 min after administration.Only the heart rate in B group at immediately after administration was lower than that in A group.Time in the recovery room in B group was (37.5 ± 6.4) min,significantly lower than A group and C group ((43.2 ± 8.9) min,(47.5 ± 9.8) min ; F =14.362 ; P ＜ 0.001).Conclusion Dexmedetomidine is a more ideal sedation drug and 0.5 μg/kg dexmedetomidine can reduce restlessness and cardiovascular reactions in patients with restlessness after general anesthesia,which is the best recommending therapeutic dose.